Figure 4.

Reduced tumour volume and AFP levels during treatment with sorafenib or sorafenib/CDDP. (A) NMRI mice were treated with CDDP (3 mg kg⁻¹ bw on days 1–3 and 14–16) and/or sorafenib (30 mg kg⁻¹ bw on days 4–13 and 17–24). Relative tumour volume was significantly lower in sorafenib-treated mice after 25 days compared with control. The combination of sorafenib and CDDP showed higher potency reaching statistical significance at day 15 (*^, **P<0.05, Bonferroni post test). Mean and s.e.m. are shown. (B) AFP levels (U ml⁻¹) in relation to tumour volume after 25 days were lower in sorafenib-treated mice. Half of the sorafenib/CDDP treated mice had elevated AFP levels compared with low tumour volumes. Shown are absolute values (P=NS, Student's t-test).